(Q36926449)

17 August 2017

1 reference

title

Non-[18F]FDG PET in clinical oncology (English)

1 reference

Fluorodeoxyglucose Positron Emission Tomography

17 August 2017

main subject

1 reference

Ashley M Groves

1 reference

17 August 2017

Thida Win

series ordinal

1 reference

17 August 2017

Simona Ben Haim

series ordinal

1 reference

17 August 2017

Peter J Ell

series ordinal

1 reference

17 August 2017

publication date

1 September 2007

1 reference

Lancet Oncology Commission

17 August 2017

published in

1 reference

17 August 2017

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

822-830

1 reference

18F-fluorodeoxyglucose PET/CT in cancer imaging.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Clinical applications of PET in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Is 11C-choline the most appropriate tracer for prostate cancer? Against

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Is 11C-choline the most appropriate tracer for prostate cancer? For.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Experience with carbon-11 choline positron emission tomography in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: comparison with 18F-FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

18F-DOPA PET/CT and neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Evaluation of primary pulmonary carcinoid tumors using FDG PET

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography with FDG to show thymic carcinoid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Breast cancer: PET imaging of estrogen receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

[18F]FLT-PET in oncology: current status and opportunities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

[18F]FLT PET for diagnosis and staging of thoracic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Clinical relevance of imaging proliferative activity in lung nodules

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Uptake of 18F-fluorocholine, 18F-fluoro-ethyl-L: -tyrosine and 18F-fluoro-2-deoxyglucose in F98 gliomas in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

O-[18F]fluoromethyl-L-tyrosine is a potential tracer for monitoring tumour response to chemotherapy using PET: an initial comparative in vivo study with deoxyglucose and thymidine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Quantitative micro positron emission tomography (PET) imaging for the in vivo determination of pancreatic islet graft survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Tumor hypoxia imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Integrin alpha v beta 3-targeted imaging of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

PET imaging of apoptosis with (64)Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970274-7

7 January 2021

10.1016/S1470-2045(07)70274-7

Identifiers

DOI

1 reference

17 August 2017

1 reference